X-FIB
A neo-epitope fragment of cross-linked fibrin generated by plasmin activity, enabling non-invasive assessment of clot resolution and wound healing dynamics in chronic and acute pathological conditions.
Key features and values
- Quantifies plasmin-mediated degradation products of cross-linked fibrin.
- Reflects the resolution phase of coagulation and wound healing processes.
- Provides a non-invasive measure of fibrinolytic activity.
- Supports monitoring of disease progression and response to therapies targeting coagulation pathways.
- Applicable in research on conditions characterized by abnormal clot formation and resolution, such as respiratory diseases and cardiovascular disorders.
- Facilitates evaluation of interventions aimed at modulating fibrinolysis.
- Complements other biomarkers for a comprehensive assessment of hemostatic balance.
Description
The X-FIB biomarker assay measures specific neo-epitope fragments resulting from plasmin-mediated degradation of cross-linked fibrin, serving as an indicator of clot resolution and wound healing dynamics. This non-invasive assay provides insights into the fibrinolytic phase of coagulation, aiding in the understanding of pathological conditions where clot formation and resolution are disrupted. By quantifying these specific degradation products, the X-FIB assay supports research into disease mechanisms, progression, and therapeutic responses in conditions such as chronic obstructive pulmonary disease and other disorders involving aberrant coagulation and fibrinolysis.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
